This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JCC-LAMP-vax

Immunomic Therapeutics, Inc.

Drug Names(s): JCC-LAMPvax

Deal Structure: JCC-LAMP-vax is a DNA vaccine intended to treat patients with mountain cedar allergy.

Lysosomal Associated Membrane Protein (LAMP) is a glycoprotein localized to the lysosomal MHC-II compartment in antigen-presenting cells (APCs). The LAMP-Vax DNA vaccine platform is taken up by APCs, which produce the protein sequence encoded by the DNA as a fusion protein with LAMP. By accessing the MHC-II immune pathway, the vaccine should convert the immune system response from an IgE response to an IgG response, resulting in a reduction in allergy symptoms.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug